Sung Yong Cho1, Suki Kang2, Dong Su Kim3, Hyung Jin Na3, Ye Jin Kim3, Young Deuk Choi4, Nam Hoon Cho5,6,7. 1. Department of Urology, Yonsei University College of Medicine, Korea and Inje University College of Medicine, Goyang, Republic of Korea. 2. Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. 3. Genomine Inc., Pohang, Republic of Korea. 4. Department of Urology, Yonsei University College of Medicine, Seoul, Republic of Korea cho1988@yuhs.ac youngd74@yuhs.ac. 5. Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea cho1988@yuhs.ac youngd74@yuhs.ac. 6. Severance Biomedical Science, Yonsei University College of Medicine, Seoul, Republic of Korea. 7. Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Republic of Korea.
Abstract
BACKGROUND/AIM: The aim of this study was to evaluate the usefulness of biomarkers related to prostate cancer metastasis and survival of patients. MATERIALS AND METHODS: Proteomics were used for detecting significant differences in protein expression among normal prostate, localized prostate cancer and metastatic cancer using 2-dimensional gel electrophoresis and mass spectrometry. mRNA expression was then examined in order to further confirm significant differences in protein expression. A total of 7 proteins were found to be differentially expressed. Immunochemistry (IHC), was also used to confirm the levels of expression of the 7 proteins in prostate cancer. Survival analysis using the candidate markers was finally performed in 98 metastatic prostate cancer patients according to IHC results. RESULTS: In metastatic lesions, proteomic analysis indicated that heat shock protein (HSP) 27, prohibitin, glutathione S-transferase 1, fibrinogen β chain, and aldehyde dehydrogenase 6A1 were up-regulated, while α1 antitrypsin, and HSP 60 were down-regulated. IHC revealed that HSP 27, ALDH6A1 and prohibitin were highly specific to metastatic tumor cells. HSP27 and prohibitin appeared more strongly in the incipient stage of cancer than metastatic cancer, and ALDH6A1 was significantly reduced in metastatic cancer (p<0.01). Of all proteins, phohibitin had the highest value in predicting survival. However, all three proteins were a stronger marker than each one separately. CONCLUSION: Trio-biomarker composed of HSP27, ALDH6A1 and prohibitin may predict survival of metastatic prostate cancer patients. Copyright
BACKGROUND/AIM: The aim of this study was to evaluate the usefulness of biomarkers related to prostate cancer metastasis and survival of patients. MATERIALS AND METHODS: Proteomics were used for detecting significant differences in protein expression among normal prostate, localized prostate cancer and metastatic cancer using 2-dimensional gel electrophoresis and mass spectrometry. mRNA expression was then examined in order to further confirm significant differences in protein expression. A total of 7 proteins were found to be differentially expressed. Immunochemistry (IHC), was also used to confirm the levels of expression of the 7 proteins in prostate cancer. Survival analysis using the candidate markers was finally performed in 98 metastatic prostate cancerpatients according to IHC results. RESULTS: In metastatic lesions, proteomic analysis indicated that heat shock protein (HSP) 27, prohibitin, glutathione S-transferase 1, fibrinogen β chain, and aldehyde dehydrogenase 6A1 were up-regulated, while α1 antitrypsin, and HSP 60 were down-regulated. IHC revealed that HSP 27, ALDH6A1 and prohibitin were highly specific to metastatic tumor cells. HSP27 and prohibitin appeared more strongly in the incipient stage of cancer than metastatic cancer, and ALDH6A1 was significantly reduced in metastatic cancer (p<0.01). Of all proteins, phohibitin had the highest value in predicting survival. However, all three proteins were a stronger marker than each one separately. CONCLUSION:Trio-biomarker composed of HSP27, ALDH6A1 and prohibitin may predict survival of metastatic prostate cancerpatients. Copyright
Authors: Jan Skoda; Jakub Neradil; Iva Staniczkova Zambo; Alena Nunukova; Peter Macsek; Karolina Borankova; Viera Dobrotkova; Pavel Nemec; Jaroslav Sterba; Renata Veselska Journal: Cancers (Basel) Date: 2020-01-13 Impact factor: 6.639